Comparison of pharmacokinetics and pharmacodynamics of Mylan's insulin glargine with Lantus in type 1 diabetes patients

Trial Profile

Comparison of pharmacokinetics and pharmacodynamics of Mylan's insulin glargine with Lantus in type 1 diabetes patients

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 22 Jul 2017 Primary endpoint (Pharmacodynamic endpoint: GIR max) has been met, according to the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 22 Jul 2017 Primary endpoint (Pharmacodynamic endpoint: AUC GIR 0-30 h:AUCGIR) has been met, according to results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 22 Jul 2017 Primary endpoint (C ins max (maximum INS).) has been met, according to the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top